Medically reviewed by Brendan Camp, MD Psoriasis affects about 3% of all adults in the United States, and Asian Americans ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Filling your portfolio with dividend-paying stocks that raise their quarterly ...

A pair of drugs that launched in 2019, Skyrizi for psoriasis and Rinvoq for arthritis, are offsetting Humira losses on their own. In the third quarter, sales of Skyrizi rose 51% year over year to ...

Heavy Industries Minister H D Kumaraswamy praised both companies' progress, hailing Tata Motors and M&M for developing this capability. The minister exuded confidence that more applicants would take ...

Many cases of mild to moderate psoriasis may be treatable with topical medication. The effectiveness of these treatments varies from person to person, depending on the severity of their psoriasis ...

Psoriasis is challenging to diagnose. Healthcare providers primarily rely on the appearance of the lesions (plaques). These can resemble skin changes caused by other conditions, such as eczema, ...